ProPhase Labs FY25 net loss narrows to $14.7 million; revenue falls 35.8% to $4.3 million

ProPhase Labs, Inc.

ProPhase Labs, Inc.

PRPH

0.00
  • ProPhase Labs posted a net loss of USD 14.7 million, or USD 1.74 per share, for fiscal 2025, narrowing from a USD 53.4 million loss.
  • Revenue fell 35.8% to USD 4.3 million, reflecting a USD 2.4 million drop in consumer products as it reduced TK Supplements sales.
  • Gross profit was USD 1.4 million, swinging from a USD 0.2 million gross margin loss; consumer products gross margin rose 7.7 percentage points to 39.9%.
  • General and administrative expense dropped to USD 19.3 million from USD 37.9 million, while interest expense climbed to USD 6.9 million.
  • Diagnostics subsidiaries halted COVID-19 testing in May 2025, filed Chapter 11 on Sept. 22, 2025, and were deconsolidated; cash was about USD 90,000 at year-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000868278-26-000005), on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.